TScan Therapeutics TCRX
NASDAQ TCRX
$0.14 -0.01 (-6.67%)
At close: Nov 19, 2026 · 4:00 PM EST

TScan Therapeutics (TCRX) Non Operating Interest Expenses (2022 - 2026)

Updated

TScan Therapeutics' Non Operating Interest Expenses was $775,000 in Q3 2026, up 10.9% from $699,000 a year earlier and up 10.9% from the prior quarter.

Analysis

TScan Therapeutics (TCRX) Non Operating Interest Expenses (2022 - 2026) Analysis & Trends

On a trailing twelve-month basis, TScan Therapeutics' Non Operating Interest Expenses was $2.87 million through Sep 30, 2026, up 0.5% year-over-year; for FY2025, it came in at $2.77 million, down 24.2% from FY2024.

  • Non Operating Interest Expenses shows a three-year compound annual growth rate of 33.0% (FY2022 to FY2025).
  • In earlier years, Non Operating Interest Expenses was $3.65 million in FY2024 (-2.8%), $3.76 million in FY2023 (+219.6%) and $1.18 million in FY2022.
  • The Q3 2026 figure marks the highest quarterly Non Operating Interest Expenses since Q4 2024.
  • Compared with a year earlier, Non Operating Interest Expenses has increased for three straight quarters, with an average decline of 11.1% over the last eight quarters.
  • The best year-over-year quarter for Non Operating Interest Expenses over five years was Q3 2023 (growth of 388.6%); the worst was Q1 2025 (a decline of 29.2%).
  • Per Business Quant data, TCRX's Non Operating Interest Expenses in the three quarters before Q3 2026 was $699,000 (Q2 2026), $689,000 (Q1 2026) and $702,000 (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 PetVivo Holdings 3,096.39 Bn 3,096.39 Bn 196,075.00 -15,526.00
2 Eli Lilly 1,202.70 Bn 1,176.32 Bn 20.46 Bn -
3 Johnson & Johnson 649.77 Bn 569.63 Bn 17.30 Bn 217.00 Mn
4 AbbVie 507.00 Bn 475.00 Bn 13.12 Bn -
5 Merck 329.70 Bn 292.64 Bn 13.19 Bn -
6 Novartis Ag 291.91 Bn 265.14 Bn - -
7 Amgen 236.26 Bn 187.91 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 207.15 Bn 182.26 Bn 6.73 Bn 269.00 Mn
9 Gsk 193.54 Bn 176.38 Bn - -
10 TScan Therapeutics 18.87 Mn -434.83 Mn - 775,000.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 775,000.00
Jun 30, 2026 699,000.00
Mar 31, 2026 689,000.00
Dec 31, 2025 702,000.00
Sep 30, 2025 699,000.00
Jun 30, 2025 689,000.00
Mar 31, 2025 679,000.00
Dec 31, 2024 784,000.00
Sep 30, 2024 958,000.00
Jun 30, 2024 952,000.00
Mar 31, 2024 959,000.00
Dec 31, 2023 852,000.00
Sep 30, 2023 982,000.00
Jun 30, 2023 969,000.00
Mar 31, 2023 956,000.00
Dec 31, 2022 975,000.00
Sep 30, 2022 201,000.00
API Access

TScan Therapeutics Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=TCRX&period=max&api_key=YOUR_API_KEY